Citius Pharmaceuticals Inc (CTXR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Citius Pharmaceuticals Inc (CTXR) has a cash flow conversion efficiency ratio of -0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.30 Million) by net assets ($69.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Citius Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
Citius Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Citius Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Citius Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See Citius Pharmaceuticals Inc cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greater Than AB
ST:GREAT
|
-0.401x |
|
ENERSIDE ENERGY EO -01
F:9O8
|
N/A |
|
Vietnam Sun Corp
VN:VNS
|
0.034x |
|
Silverline Endustri ve Ticaret AS
IS:SILVR
|
-0.012x |
|
Greenbriar Capital Corp
V:GRB
|
-0.048x |
|
Farmaceutica R
RO:RMAH
|
N/A |
|
Omnisystem Co.Ltd
KQ:057540
|
-0.021x |
|
Heart Test Laboratories Inc. Common Stock
NASDAQ:HSCS
|
-7.416x |
Annual Cash Flow Conversion Efficiency for Citius Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Citius Pharmaceuticals Inc from 2011 to 2025. View CTXR stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $77.53 Million | $-26.55 Million | -0.342x | +10.01% |
| 2024-09-30 | $74.10 Million | $-28.20 Million | -0.381x | -19.74% |
| 2023-09-30 | $91.43 Million | $-29.06 Million | -0.318x | -15.91% |
| 2022-09-30 | $103.43 Million | $-28.36 Million | -0.274x | -50.15% |
| 2021-09-30 | $132.78 Million | $-24.25 Million | -0.183x | +63.68% |
| 2020-09-30 | $33.67 Million | $-16.93 Million | -0.503x | +1.44% |
| 2019-09-30 | $24.38 Million | $-12.44 Million | -0.510x | -25.61% |
| 2018-09-30 | $27.87 Million | $-11.32 Million | -0.406x | -11.83% |
| 2017-09-30 | $21.95 Million | $-7.97 Million | -0.363x | -3.20% |
| 2016-09-30 | $16.77 Million | $-5.90 Million | -0.352x | -109.37% |
| 2015-09-30 | $-635.21K | $-2.39 Million | 3.755x | +295.18% |
| 2014-09-30 | $-741.93K | $-705.05K | 0.950x | +530.18% |
| 2013-09-30 | $93.27K | $-20.60K | -0.221x | -149.83% |
| 2012-09-30 | $-45.85K | $-20.32K | 0.443x | -49.14% |
| 2011-09-30 | $-23.84K | $-20.78K | 0.872x | -- |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more